Development

This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.

The COVID-19 pandemic helped to showcase RNA molecules and their therapeutic potential. There were also lessons learned in terms of drug delivery, manufacturing, logistics, and storage.

Big data is a natural for pharmaceutical industry players that have not already embraced it.

Messenger RNA is inherently unstable and thus requires unique solutions to protect its cohesion.

This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.

Biologic drug development requires relevant bioassays to measure and help predict cellular response.

Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.

Webinar Date/Time: Tue, Jan 24, 2023 11:00 AM EST

Sosei Heptares and Eli Lilly have entered a multi-target collaboration and license agreement in diabetes and metabolic diseases.

GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.

AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.

Emmes’ new facility is designed to support clients conducting cell and gene therapy research worldwide.

Particle engineering can be a resourceful tool to advance drug candidates by offering drug delivery innovation.

Deeper biological understanding and technology innovations have improved the fate of ADC development.

Through the integration of human expertise, artificial intelligence, and automation robotics, bio/pharma companies can more efficiently target drug discovery efforts with bigger payoff.

Generate Biomedicines published a preprint describing technology that can generate novel proteins towards desired functional or other properties.

The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations.

Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.

Science news can be just so weird, or weirdly useful, that everything else recedes as we ponder whether it is true and what consequences it might bring.

Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.

A novel mathematical approach for fitting concentration-response curves is proposed that offers a more accurate estimation of potency data.

Companies need to consider and address formulation challenges to employ a successful reformulation strategy.

The Start-Up Market at CPHI Barcelona brings together 27 start-ups, innovators, and small enterprises from across the pharma landscape.

New medications show exciting outcomes for weight loss.

Increasing molecular diversity is creating a need for the reinvention of process development and control strategies.

Pharma companies set goals and adopt more sustainable alternatives.

Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.

FDA has accepted Ashland’s Viatel bioresorbable mPEG-PDLLA pharmaceutical excipient into the FDA Novel Excipient Review Pilot Program.

Roquette has launched excipients PEARLITOL CR-H and PEARLITOL 200 GT.

AstraZeneca’s Imjudo (tremelimumab) was approved by FDA in combination with Imfinzi (durvalumab) for treating unresectable liver cancer.